Gynecologic Oncology Practice Questions

Q: Which of the following is not a risk factor for carcinoma of the cervix?

Low parity. **Explanation:** The primary etiology of cervical carcinoma is persistent infection with **High-Risk Human Papillomavirus (HPV)**, specifically types 16 and 18. Therefore, risk factors are predominantly those that increase exposure to HPV or impair the body’s ability to clear the virus. **Why "Low Parity" is the correct answer:** In contrast to endometrial and ovarian cancers (where low parity is a risk factor), **High Parity (Multiparity)** is a documented risk factor for cervical cancer. Frequent pregnancies cause repeated trauma to the cervix and maintain the squamocolumnar junction (transformation zone) in an everted position on the ectocervix for longer periods, increasing susceptibility to HPV infection. Thus, low parity is actually protective or neutral, not a risk factor. **Analysis of Incorrect Options:** * **Multiple sexual partners:** This is the most significant risk factor as it directly increases the probability of exposure to HPV. * **Early sexual intercourse (<16 years):** The adolescent cervix has a large area of **metaplastic epithelium** (transformation zone), which is highly vulnerable to HPV integration. * **Smoking:** Tobacco by-products (cotinine) concentrate in the cervical mucus and damage the DNA of Langerhans cells, impairing local mucosal immunity and preventing the clearance of HPV. **High-Yield Clinical Pearls for NEET-PG:** * **Most common histological type:** Squamous cell carcinoma (80%). * **OCP Use:** Long-term use (>5 years) is a known risk factor for cervical cancer (unlike its protective effect in ovarian/endometrial cancer). * **Immunosuppression:** HIV-positive women have a significantly higher risk and faster progression of CIN to invasive cancer. * **Screening:** The transformation zone is the most common site of origin for cervical cancer.

Q: During population-based screening programs, a 40-year-old lady was found to have cervical intraepithelial neoplasia. Which of the following is the appropriate treatment modality for this patient?

All of the above. **Explanation:** The management of Cervical Intraepithelial Neoplasia (CIN) is determined by the grade of the lesion, the visibility of the transformation zone (TZ), and the patient's clinical profile. Treatment modalities are broadly classified into **Ablative** and **Excisional** techniques. 1. **Ablative Techniques (e.g., Cryotherapy):** These destroy the abnormal tissue in situ. Cryotherapy is highly effective for low-grade lesions (CIN 1) or CIN 2/3 when the entire lesion is visible, the transformation zone is Type 1 (fully ectocervical), and there is no suspicion of glandular or invasive disease. 2. **Excisional Techniques (e.g., LEEP and Cold Knife Conization):** These remove the abnormal tissue, providing a specimen for histopathological review. * **LEEP (Loop Electrosurgical Excision Procedure):** The most common treatment for CIN 2/3. It is quick, can be done under local anesthesia, and preserves the specimen. * **Cold Knife Conization (CKC):** The gold standard for suspected microinvasion, glandular disease (AIS), or when the squamocolumnar junction is not visible (Type 3 TZ). **Why "All of the above" is correct:** The question mentions "Cervical Intraepithelial Neoplasia" generally. Depending on the specific grade (CIN 1, 2, or 3) and the visibility of the transformation zone, any of these three modalities could be the "appropriate" choice. In a screening program context, the choice is tailored to the patient's specific diagnostic findings. **High-Yield Clinical Pearls for NEET-PG:** * **See-and-Treat:** LEEP is often preferred in "see-and-treat" protocols to reduce loss to follow-up. * **Transformation Zone (TZ):** Ablative methods (Cryotherapy) are **contraindicated** if the TZ is not fully visible (Type 3). * **Pregnancy:** Treatment of CIN is generally deferred until postpartum, unless invasive cancer is suspected. * **Follow-up:** Post-treatment follow-up involves HPV testing or Co-testing at 12 months.

Q: Point B in the treatment of carcinoma of the cervix by radiotherapy corresponds to which anatomical structure?

Obturator nodes. ### Explanation In the Manchester system of brachytherapy for cervical cancer, **Point B** is a crucial dosimetric landmark used to assess the dose delivered to the lateral pelvic walls and regional lymph nodes. **Why Option A is Correct:** Point B is located **2 cm superior** to the external cervical os (or the lateral vaginal fornix) and **5 cm lateral** to the midline. Anatomically, this point represents the **obturator lymph nodes** and the lateral pelvic wall. While Point A represents the paracervical area (where the ureter and uterine artery cross), Point B is designed to monitor the dose to the pelvic side wall to ensure adequate treatment of the primary lymphatic drainage sites while avoiding toxicity to the surrounding structures. **Why the Other Options are Incorrect:** * **B. Mackenrodt’s ligament (Cardinal ligament):** This structure is located more medially and is better represented by **Point A** (2 cm superior and 2 cm lateral to the midline), which corresponds to the paracervical triangle. * **C. Ischial tuberosity:** This is a bony landmark of the pelvis used in clinical pelvimetry but is not a reference point for radiotherapy dosing in the Manchester system. * **D. Round ligament:** This ligament extends from the uterine horns to the labia majora; it is not a primary target or a reference landmark for cervical brachytherapy. **High-Yield Clinical Pearls for NEET-PG:** * **Point A:** 2 cm up, 2 cm lateral. Represents the crossing of the **Ureter and Uterine Artery**. It is the point of "dosage prescription." * **Point B:** 2 cm up, 5 cm lateral. Represents **Obturator nodes**. It is the point of "dosage monitoring." * **ICRU 38/89:** Modern radiotherapy is shifting from these 2D points toward 3D volume-based planning (GEC-ESTRO guidelines), but Point A and B remain high-yield for exams. * The dose at Point B is typically **1/3rd to 1/4th** of the dose at Point A.

Q: Which tumor marker is secreted in choriocarcinoma?

HCG. **Explanation:** **Choriocarcinoma** is a highly malignant germ cell tumor or gestational trophoblastic neoplasm (GTN) arising from the chorionic epithelium. The correct answer is **HCG (Human Chorionic Gonadotropin)** because the tumor is composed of syncytiotrophoblasts and cytotrophoblasts. Syncytiotrophoblasts are physiologically responsible for the secretion of HCG. In choriocarcinoma, HCG levels are typically markedly elevated and serve as a sensitive marker for diagnosis, monitoring treatment response, and detecting recurrence. **Analysis of Incorrect Options:** * **A. CEA (Carcinoembryonic Antigen):** This is a non-specific oncofetal antigen primarily used as a marker for colorectal carcinoma and other GI tract malignancies. * **B. Prolactin:** This is a hormone secreted by the anterior pituitary gland. While elevated in prolactinomas, it has no diagnostic association with choriocarcinoma. * **C. Alpha-fetoprotein (AFP):** This is the characteristic marker for Yolk Sac Tumors (Endodermal Sinus Tumors) and Hepatocellular Carcinoma. **High-Yield Clinical Pearls for NEET-PG:** * **Golden Rule:** HCG is the "universal marker" for Gestational Trophoblastic Disease (Hydatidiform mole, Invasive mole, and Choriocarcinoma). * **Histology:** Choriocarcinoma is unique because it is characterized by a **dimorphic population** of cells (syncytiotrophoblasts and cytotrophoblasts) and a distinct **absence of chorionic villi**. * **Metastasis:** It spreads hematogenously; the **lung** is the most common site of metastasis (look for "cannonball secondaries" on X-ray). * **Treatment:** It is highly chemosensitive; **Methotrexate** is the first-line agent for low-risk cases.

Q: What is the standard treatment for stage-I endometrial carcinoma?

Surgery. **Explanation:** The primary treatment for **Stage I endometrial carcinoma** is **Surgery**. According to FIGO staging, Stage I is confined to the corpus uteri. The standard surgical procedure is **Total Laparoscopic/Abdominal Hysterectomy with Bilateral Salpingo-Oophorectomy (TAH + BSO)**. For high-risk cases, pelvic and para-aortic lymphadenectomy or sentinel lymph node mapping is also performed for surgical staging. Surgery is curative for the majority of patients in this early stage. **Why other options are incorrect:** * **Radiotherapy:** This is primarily used as **adjuvant therapy** (post-surgery) to reduce local recurrence in patients with high-risk features (e.g., deep myometrial invasion or high grade). It is only the primary treatment if the patient is medically unfit for surgery. * **Chemotherapy:** This is reserved for advanced stages (Stage III and IV) or recurrent disease. It is not the first-line treatment for Stage I. * **Hormone Therapy:** High-dose progestins (e.g., Megestrol) are used only in specific scenarios, such as fertility-sparing treatment in young patients with Grade 1 Stage IA disease or for palliation in advanced cases. **High-Yield Clinical Pearls for NEET-PG:** * **FIGO Staging:** Endometrial cancer is **surgically staged**. * **Stage IA:** Tumor limited to <50% myometrium; **Stage IB:** Invasion ≥50% myometrium. * **Most common histological type:** Endometrioid adenocarcinoma (Type I), which is estrogen-dependent. * **Risk Factors:** Obesity (most common), Nulliparity, Early menarche/Late menopause, and Lynch Syndrome (HNPCC).

Q: According to the FIGO staging, what is the characteristic of Grade 3 endometrial tumors?

>50% non-squamous or non-morular growth pattern. The FIGO (International Federation of Gynecology and Obstetrics) grading system for endometrial carcinoma is based on the architectural growth pattern of the tumor, specifically the proportion of **solid, non-glandular, non-squamous growth**. ### **Explanation of the Correct Answer** **Grade 3 (High Grade)** is defined as a tumor where **>50%** of the growth pattern is solid (non-squamous or non-morular). These tumors are poorly differentiated, exhibit significant nuclear atypia, and carry a worse prognosis compared to lower grades. ### **Analysis of Incorrect Options** * **Option A ( 75%):** This is not a standard FIGO cutoff. The FIGO system strictly uses the 5% and 50% thresholds for grading. ### **High-Yield Clinical Pearls for NEET-PG** 1. **The "Nuclear Rule":** If there is significant (Grade 3) nuclear atypia (large, pleomorphic nuclei with prominent nucleoli) in a tumor that otherwise looks like Grade 1 or 2, the overall FIGO grade is **increased by one**. 2. **Non-endometrioid subtypes:** Serous, clear cell, and carcinosarcomas are considered **Grade 3 by definition** regardless of their growth pattern. 3. **Squamous differentiation:** Solid areas of squamous differentiation (morules) are **excluded** from the percentage calculation when determining the grade. 4. **Prognostic Significance:** Grade is one of the most important predictors of lymph node metastasis and overall survival in endometrial cancer.

Q: A 45-year-old female presents with bilateral ovarian mass, ascites, and omental caking on CT scan. What is the most likely diagnosis?

Malignant epithelial ovarian tumor. **Explanation:** The clinical presentation of **bilateral ovarian masses**, **ascites**, and **omental caking** (thickening of the omentum due to metastatic infiltration) is the classic triad for advanced-stage **Malignant Epithelial Ovarian Tumor (EOC)**. EOC is the most common type of ovarian cancer in women over 40. It typically spreads via exfoliation of cells into the peritoneal cavity (seeding), leading to peritoneal carcinomatosis, ascites, and the characteristic "omental cake" seen on imaging. **Analysis of Options:** * **Option A (Benign ovarian tumor):** Benign tumors (like serous cystadenomas) are usually unilateral, slow-growing, and do not cause omental caking or significant ascites. * **Option C (Dysgerminoma):** This is a Germ Cell Tumor (GCT) typically seen in younger women (adolescents/early 20s). While it can be bilateral (10-15%), it usually presents as a solid mass rather than widespread peritoneal disease. * **Option D (Lymphoma):** Primary ovarian lymphoma is extremely rare. While it can be bilateral, it does not typically present with the classic omental caking seen in epithelial carcinomas. **NEET-PG High-Yield Pearls:** * **Most common EOC:** Serous cystadenocarcinoma (often bilateral). * **Tumor Marker:** **CA-125** is the primary marker for EOC monitoring. * **Omental Caking:** This is a pathognomonic radiological sign for peritoneal carcinomatosis, most commonly secondary to ovarian, gastric, or colonic malignancy. * **Risk Factors:** Nulliparity, early menarche, late menopause, and BRCA1/BRCA2 mutations. Combined Oral Contraceptive Pills (COCPs) are protective.

Question 1

Carcinoma cervix is more common in which of the following?

Accepted Answer

Multiparity

Answer

HIV patient

Answer

Smoking

Answer

Nulliparity

Question 2

Which of the following is not a risk factor for carcinoma of the cervix?

Accepted Answer

Low parity

Answer

Multiple sexual partners

Answer

Early sexual intercourse (before 16 years of age)

Answer

Smoking

Question 3

During population-based screening programs, a 40-year-old lady was found to have cervical intraepithelial neoplasia. Which of the following is the appropriate treatment modality for this patient?

Accepted Answer

All of the above

Answer

Cryotherapy

Answer

Loop electrosurgical excision procedure (LEEP)

Answer

Cold knife conization

Question 4

Point B in the treatment of carcinoma of the cervix by radiotherapy corresponds to which anatomical structure?

Accepted Answer

Obturator nodes

Answer

Machenrodt's ligament

Answer

Ischial tuberosity

Answer

Round ligament

Question 5

Which tumor marker is secreted in choriocarcinoma?

Accepted Answer

HCG

Answer

CEA

Answer

Prolactin

Answer

Alpha-fetoprotein

Question 6

What is the standard treatment for stage-I endometrial carcinoma?

Accepted Answer

Surgery

Answer

Chemotherapy

Answer

Radiotherapy

Answer

Hormone therapy

Question 7

According to the FIGO staging, what is the characteristic of Grade 3 endometrial tumors?

Accepted Answer

>50% non-squamous or non-morular growth pattern

Answer

<5% non-squamous or non-morular growth pattern

Answer

6%-50% non-squamous or non-morular growth pattern

Answer

>75% non-squamous or non-morular growth pattern

Question 8

A 45-year-old female presents with bilateral ovarian mass, ascites, and omental caking on CT scan. What is the most likely diagnosis?

Accepted Answer

Malignant epithelial ovarian tumor

Answer

Benign ovarian tumor

Answer

Dysgerminoma of the ovary

Answer

Lymphoma of the ovary

Question 9

According to cancer cervix tumor size, which of the following is the cut-off size of tumor up till which primary surgical treatment is the best option?

Accepted Answer

Less than 4 cm tumor size

Answer

All sizes of tumors have good results

Answer

Less than 5 mm depth of invasion

Answer

Less than 2 cm tumor size

Question 10

During screening for cervical cancer in a community, a Pap smear of a 51-year-old female shows abnormal cytology. What is the best next logical procedure?

Accepted Answer

Colposcopy and biopsy

Answer

Conization

Answer

Hysterectomy

Answer

HPV viral DNA testing

Gynecologic Oncology — MCQs

Gynecologic Oncology — MCQs

On this page

Practice by Chapter

Want unlimited practice?